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ABSTRACT OF THE DISSERTATION
HPV16 E6* Induces Oxidative Stress and DNA Damage
by
Vonetta M. Williams
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, June 2014
Dr. Penelope J. Duerksen-Hughes, Chairperson

High risk types of Human Papillomavirus are the causative agents of virtually all
cases of cervical cancer, 50-90% of other anogenital cancers and approximately 30% of
oral and pharyngeal cancers. The high-risk types encode two viral oncogenes, E6 and E7,
which work together to initiate cell transformation. The approximately 50 amino acid
product of the E6* transcript is expressed during the early stages of HPV infection. In
this study, we found that expression of E6* increased the level of reactive oxygen species
(ROS) in both HPV+ and HPV- cells. This increased oxidative stress led to higher levels
of DNA damage. The observed increase in ROS may be due to a decrease in cellular antioxidant activity, as we found that E6* expression also led to decreased expression of
SOD and Gpx, These studies indicate that E6* may play an important role in virusinduced mutagenesis by increasing oxidative stress and DNA damage.

xii

CHAPTER ONE
INTRODUCTION

The Human Papillomavirus (HPV), a double strand DNA virus, was first
identified in skin cells in the 1950’s. They are now known to infect basal keratinocytes in
the skin and mucosal membranes. They are the causative agents of diseases that affect
both the cutaneous and mucosal epithelia, from common warts to invasive carcinoma.
Harald zur Hausen, who received the 2008 Nobel Prize for his work, was the first to link
HPV infection to cervical neoplasia (zur Hausen, 1976). HPVs are divided into more
than 100 different strains or types based on sequence differences within their L1 gene
(Calleja-Macias et al., 2005). HPV types are designated “low-risk” or “high-risk”, based
on whether they are known to cause benign or cancerous lesions (Ault, 2007). HPV
infection is the most common sexually transmitted infection with an estimated point
prevalence of about 43 to 62% (Giuliano et al., 2008; Hariri et al., 2011). High-risk HPV
infections are asymptomatic and the vast majority of individuals infected with the virus
will clear the infection without ever progressing to cervical cancer. However, in some
cases due to the presence of certain risk factors such as smoking, co-infection with other
sexually transmitted diseases and immunologic deficiency the infection persists and may
eventually lead to cancer. Current data provides evidence that HPV is responsible for a
considerable health burden worldwide, as these viruses are involved in the etiology of a
significant percentage of both anogenital (anal, penile, vaginal and vulvar) and
oropharyngeal cancers. Approximately 4-5% of all cancers worldwide are associated with
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HPV infection (Parkin & Bray, 2006). High-risk oncogenic human papillomaviruses
have been shown to be the etiological agents of cervical cancer, the second most common
cancer in women worldwide, and virtually all cases of cervical cancer and anogenital
cancer are caused by about 15 types of human papillomavirus (Guccione, Pim, & Banks,
2004; Walboomers et al., 1999; Weaver, 2006). High-risk papillomaviruses DNA has
now been detected in over 70% of cases of oropharyngeal cancer in patient samples
collected in the US between 2000-2004 (Chaturvedi et al., 2011).
While the incidence of cervical cancer in the US has declined dramatically
(almost 75%) over the last several decades since the 1940’s due to better screening with
the Pap smear and is expected to decrease even further with the widespread usage of the
HPV vaccines, the same is not true for other HPV-related cancers (Scarinci et al., 2010).
A 2014 review in Oral Oncology notes that there has been an increase over the last three
decades in the incidence of squamous cell carcinoma of the oropharynx as a result not of
smoking but rather HPV infection (Pytynia, Dahlstrom, & Sturgis, 2014). Additionally,
the incidence of HPV-related anal cancer has been increasing steadily in both men and
women over the last few decades with an exponential increase particularly among the
men who have sex with men (MSM) group (Frisch, 2002).
The high-risk strains HPV-16, HPV-18, HPV 45 and HPV-31 together are
responsible for the majority of cases of cervical cancer, with HPV-16 responsible for
almost 60% alone (Muñoz et al., 2003). Even with recent advances in the sequencing of
HPV genomes, details of viral gene expression and regulation remain incomplete.
Therefore, there remains a need to explore the mechanisms of HPV-associated cancer
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progression, and in particular, the incompletely understood process of HR-HPV
integration.

HPV Genome Structure and Function
Papillomavirus genomes consist of double-stranded circular DNA approximately
8 kb in size, containing approximately 8 open reading frames (ORF) which are
transcribed as polycistronic messages from a single DNA strand. The genome can be
divided into three regions: an early region, a late region and long control region. The
early region encodes six common open reading frames, E1, E2, E4, E5, E6 and E7. The
E3 ORF does not encode a protein. The late region, positioned downstream of the early
region, encodes the ORFs for the L1 and L2 capsid proteins. The long control region
(LCR) or upstream regulatory region (URR) consists of 400-700 base pairs in length and
holds the origin of replication and several transcription factor binding sites, but lacks any
protein-coding function. However, the LCR does contain RNA regulatory signals in the
late 3’UTR (3’-untranslated region). The proteins encoded from the early region are
regulatory in function. Some of their functions include participation in HPV genome
replication and transcription, cell cycle control, cell signaling and in the control of
apoptosis.
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The E1 protein functions as a viral initiator and is a DNA helicase/ATPase. The
E2 protein is a DNA binding protein that regulates viral gene expression (Hegde, 2002).
It can also inhibit the cell cycle, and when expressed at high levels can induce apoptosis
(Desaintes, Demeret, Goyat, Yaniv, & Thierry, 1997). Together, these two proteins form
an E1-E2 ori-complex that is necessary for the initiation of DNA replication and the
maintenance of viral episomes in cells (Behren et al., 2005; Berg & Stenlund, 1997;
Desaintes et al., 1997). Loss of E2 function due to disruption of the E2 ORF almost
invariably accompanies viral DNA integration. This loss of E2 function leads to
increased levels of the E6 and E7 oncoproteins that are necessary for creating and
maintaining a transformed state in cells (Bosch et al., 1990). The E4 protein contributes
to viral release by perturbing the cytokeratin network and increasing cellular fragility
(Raj, Berguerand, Southern, Doorbar, & Beard, 2004).
E5, E6 and E7 are considered the viral oncoproteins. Although less well-known
than the E6 and E7 oncoproteins, E5 is considered an oncoprotein because of its ability to
transform cells in culture and increase tumorigenicity in mice (Oelze, Kartenbeck,
Crusius, & Alonso, 1995; Oh et al., 2009). Also, it has been found to be essential for the
promotion and progression stages of carcinogenesis (Maufort, Genther Williams, Pitot, &
Lambert, 2007). The oncoproteins E6 and E7 from high-risk strains of the HPV virus are
crucial for the induction and maintenance of the transformed phenotype in cells (Lembo
et al., 2006; von Knebel Doeberitz, Bauknecht, Bartsch, & zur Hausen, 1991). Studies
have established that the E7 protein binds to, inactivates and accelerates the degradation
of pRB and related proteins (Dyson, Howley, Munger, & Harlow, 1989). The HPV E7
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protein also targets cell cycle and regulatory genes, resulting in the up-regulation of genes
required for the G1/S transition and DNA synthesis.
The HPV 16 E6 protein, which is the focus of this proposal, consists of 151 amino
acids with two zinc fingers characterized by the CXXC motif (Barbosa, Lowy, &
Schiller, 1989; S. Tungteakkhun & P. Duerksen-Hughes, 2008). The E6 oncoprotein has
been shown to stimulate the degradation of the p53 tumor suppressor protein by forming
a ternary complex with the E6AP ubiquitin protein ligase and p53 (J. M. Huibregtse,
Scheffner, & Howley, 1991; J M Huibregtse, Scheffner, & Howley, 1993; Scheffner,
Werness, Huibregtse, Levine, & Howley, 1990; Werness, Levine, & Howley, 1990).
However, E6 is multifunctional and has other activities that also contribute to
malignancy. For example, it can modulate the transcription of cellular and viral
promoters and the increase of cellular telomerase activity (Klingelhutz, Foster, &
McDougall, 1996; Morjani et al., 2001). E6 also interacts with and accelerates the
degradation of cellular proteins such as Bak and FADD, which are involved in apoptotic
pathways (S. Tungteakkhun & P. Duerksen-Hughes, 2008). Our laboratory has shown
that E6 can inhibit TNF-mediated apoptosis in cells by binding to the death domain of
TNF-R1, preventing interaction with TRADD (M. Filippova, Song, Connolly, Dermody,
& Duerksen-Hughes, 2002). We have also demonstrated that E6 binds to FADD,
mediates its degradation, and thus prevents FAS-induced apoptosis (M. Filippova,
Parkhurst, & Duerksen-Hughes, 2004). Cumulatively, these functions contribute to the
oncogenicity of the E6 oncoprotein.
In addition to the full-length E6 transcript, several truncated transcripts can be
identified that result from differential splicing (David Pim, Paola Massimi, & Lawrence
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Banks, 1997; Sherman & Schlegel, 1996). E6 is expressed as a full-length version (E6L)
with several splice variants, including E6*I and E6*II. The splice variants E6*I and
E6*II differ from each other by a few amino acids at the C-terminus, with E6*I being
more abundant in cells. The truncated proteins are referred to collectively as E6*, while
the full-length version is called E6 (full-length) (E6) (Tungteakkhun, Filippova, Fodor, &
Duerksen-Hughes). Research from our lab has generated strong evidence that these
isoforms play separate and significant roles in cell signaling pathways (Maria Filippova
et al., 2007; Tungteakkhun et al.). These findings support the idea that viruses can utilize
differential splicing to expand the number of actions that they can perform.
Our laboratory has contributed significantly to the current understanding of how
HPV16 E6 modulates apoptosis. We have demonstrated that the full-length isoform is
able to protect cells from apoptosis mediated by TNF, Fas and TRAIL (M. Filippova et
al., 2002; Garnett, Filippova, & Duerksen-Hughes, 2006; Sandy S. Tungteakkhun, Maria
Filippova, Jonathan W. Neidigh, Nadja Fodor, & Penelope J. Duerksen-Hughes, 2008).
We have also demonstrated that the E6* splice isoform, which was previously thought to
have no functional activity, is able to bind to and stabilize the procaspase 8 protein and
thereby increase its expression (S. S. Tungteakkhun, M. Filippova, J. W. Neidigh, N.
Fodor, & P. J. Duerksen-Hughes, 2008).

The Viral Life-Cycle
Infection with the human papillomavirus occurs at a site of wounding in the basal
epithelial cells, and differentiation of the host cell is required for productive infection by
the HPVs. As a consequence, the HPV life cycle is linked to the differentiation of the
host’s epithelial cells. The HPV life cycle can be separated into two stages, a non7

productive and a productive stage. In the non-productive stage, following entry into the
basal epithelial cells, the HPV genome is established as an extrachromasomal
autonomous element (episome). Approximately 50 copies of the episomal HPV genome
are present at this stage, which allows for low level expression of some, but not all of the
HPV genes. In order to establish a steady state level of viral genomes, the virus replicates
its DNA in concert with division of basal and parabasal cells.
As the life-cycle continues, subsets of daughter cells detach from the basement
membrane and differentiate. It is here in the terminally differentiated layers of the
epithelium that the productive stage occurs. The viral E6 and E7 proteins reactivate the
cell’s DNA replication machinery and the virus amplifies its genome (Bedell et al., 1991;
von Knebel Doeberitz et al., 1991). During this time, the E1 and E4 proteins are
synthesized, along with the capsid proteins, and infectious virions are assembled. These
virions are released into the environment as the epithelium’s upper layer is shed.
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In low risk strains of the virus, replication begins in cells that are still
proliferating. However, in high risk strains, the replicative phase is confined to more
differentiated cells that have already exited the cell cycle and are no longer carrying out
DNA synthesis (John Doorbar et al., 1997).

HPV Integration
Although 95% of patients with precancerous lesions of the cervix harbor HPV,
only a small fraction of these eventually progress to invasive carcinoma (Hopman et al.,
2006). Three premalignant stages, cervical intraepithelial neoplasia 1 (CIN1), cervical
intraepithelial neoplasia 2 (CIN2), and cervical intraepithelial neoplasia 3 (CIN3) precede
development of invasive carcinoma (invCA). CIN1 lesions typically regress
spontaneously, with only a few lesions progressing to CIN2/CIN3 and eventually to
invasive carcinoma (Snijders, Steenbergen, Heideman, & Meijer, 2006). It is therefore
clear that although HR-HPV infection is a necessary event in cervical carcinogenesis, it is
not sufficient for the pathogenesis of cervical cancer. Progression of cervical cancer in
HPV infected women is tightly linked to integration status, and the frequency with which
HR-HPV is found integrated in cervical cancers is consistently high. For example, it has
been reported that 100% of HPV18-, 80% of HPV16- and 81% of HPV31- positive
cancers show viral integration (Cullen, Reid, Campion, & Lorincz, 1991; Pirami, Giache,
& Becciolini, 1997).
For these reasons, integration of the HR-HPV genome is usually considered a
necessary event in the progression to cervical and other anogenital cancers, with an
increase in the presence of integrated viral DNA correlating with disease progression
(Arias-Pulido, Peyton, Joste, Vargas, & Wheeler, 2006; Briolat et al., 2007; Daniel,
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Rangarajan, Mukherjee, Vallikad, & Krishna, 1997; Hudelist et al., 2004; Peter et al.;
Schwarz et al., 1985; Vinokurova et al., 2008). Evidence indicates that the HPV genome
is present in episomal form in early low-grade lesions (such as CIN1 and CIN2) while
integration of the viral genome is observed in advanced stages of precancer and invasive
carcinoma, suggesting that integration of HR-HPV genomes into the host genome occurs
relatively late in the pathogenesis of cancer (Cullen et al., 1991; Wentzensen,
Vinokurova, & Doeberitz, 2004). Furthermore, inflammation-mediated DNA damage
frequently precedes the genomic abnormalities caused by HPV oncoproteins (Hiraku et
al., 2007) thereby suggesting that HPV integration is involved in neoplastic progression.
Integration typically results in the increased expression and stability of transcripts
encoding the viral oncogenes E6 and E7, which are known to inactivate and/or accelerate
the degradation of numerous cellular proteins, including pRB (retinoblastoma protein)
(E7) and p53 (tumor protein 53) (E6) (Hausen, 2000; S. Jeon & P. F. Lambert, 1995;
Munger et al., 2004). The E2 ORF has been identified as the preferential site of
integration because it is more commonly disrupted or deleted than any other site
(Badaracco, Venuti, Sedati, & Marcante, 2002). The E2 protein negatively regulates E6
and E7 expression, therefore, loss of this ORF during integration results in increased
expression of the transforming E6 and E7 oncoproteins (Romanczuk & Howley, 1992).
Thus, integration of the HPV genome results in the enhanced, deregulated expression of
the viral oncogenes, E6 and E7, which are responsible for cellular transformation. In
addition, it is thought that viral DNA integration disrupts critical cellular genes (Ferber et
al., 2003) (Ferber et al., 0000; Popescu & DiPaolo, 1990). Both of these factors would
contribute to neoplastic progression.
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Relatively little is known of the process whereby HPV genomes become
integrated into that of the host. However, several studies have suggested that DNA
damage and agents that can induce DNA damage may play a role in HPV integration. A
2007 study in W12 cells, which stably maintain HPV16 episomes, demonstrated that
when double strand breaks (DSBs) are generated due to Ku70 depletion, new HPV16
viral integration events occurred. Ku70 is a crucial mediator of DSB non-homologous
end joining (NHEJ). This data indicates that DSBs may be associated with HPV 16
episome loss and integration in cervical cancer (D. Winder et al., 2007). In the case of
another DNA virus, Hepatitis B, that causes hepatocellular cancer and in which viral
DNA integration coincides with severe dysplasia, studies have shown that integration
frequency increases with DNA damage (M. Dandri et al., 2002). Therefore, it is
reasonable to expect that the integration of viral DNA into that of the host would be
enhanced by damage to both the viral episome and the host DNA, as this would create a
site for integration.
Inflammation mediated DNA damage therefore provides a potential mechanism
by which HPV integration could occur in the progression of cervical cancer. Indeed,
inflammation has been implicated in the progression of a variety of cancers, and it has
been suggested that the excessive amounts of reactive oxygen and nitrogen species
produced during chronic inflammation play a role in carcinogenesis by promoting DNA
damage (Kawanishi, Hiraku, Pinlaor, & Ma, 2006). In the case of HPV-associated
cancers, inflammation would also facilitate the integration of the viral genome by
inducing breaks in both the viral and host genomes.
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Cofactors for HPV Oncogenesis
Several co-factors, in addition to HPV infection, have been associated with the
progression to cancer. Smoking, long term use of oral contraceptives and parity have all
been suggested to serve as co-factors for the development of cervical cancer (Almonte et
al., 2008). Among these cofactors, the case for smoking as a cofactor is perhaps the
strongest, as evidence shows that it precedes the development of cervical pre-cancer and
cancer, and increases the risk of developing cervical cancer in HPV positive women
(Deacon et al., 2000; Plummer et al., 2003). Smoking leads to DNA-adduct formation
and thus DNA damage, a possible mechanism for cancer development. High parity may
also be mechanistically linked, as it causes cervical trauma and cellular oxidative and
nitrosative stress, all of which can lead to DNA damage and contribute to cancer
progression. Women with seven or more full-term pregnancies (FTPs) are at higher risk
of developing cervical cancer than those with only one or two, indicating that as the
number of FTPs increase so does the risk of developing cervical cancer (Almonte et al.,
2008). Women also increase their risk of cervical cancer through the long term use of oral
contraceptives (La Vecchia & Boccia, 2014).
Another co-factor involved in the development of cervical cancer is co-infection
with other sexually transmitted diseases (STDs), either viral or bacterial in nature. Such
infections can cause inflammation, and in HPV-infected women, cervical inflammation is
associated with cervical neoplasia (Castle & Giuliano, 2003; Castle et al., 2001). It is
important to note that this inflammation is not typically due to HPV itself, in part because
the immune system is largely ineffective against the human papillomavirus. HPV infects
keratinocytes, which are distant from immune centers and have a naturally short lifespan.
In addition, the virus does not need to destroy the cell, and so inflammation is not
13

typically triggered (Stanley, 2006). Despite this, high levels of inflammatory mediators
are observed in cervical cancer. For example, COX-2, an enzyme responsible for
prostaglandin formation, is over-expressed in cervical cancer (Kim et al., 2004; Kulkarni
et al., 2001). COX are a family of enzymes that catalyze the formation of prostaglandins
from arachidonic acid (Saldivar et al., 2007). The COX-2 isoform is induced in response
to inflammatory factors and is expressed in early stage premalignant lesions, including
cervical tissues (Saldivar et al., 2007). One study found that 100% of the cervical cancer
samples tested showed COX-2 expression, compared with only 7.7% in normal samples
(Hammes et al., 2008). Also, Nuclear factor-κ[kappa]B (NFκB), a master transcription
factor that is essential for promoting inflammation associated carcinogenesis (Pikarsky et
al., 2004; Ravi & Bedi, 2004), is over-expressed in cervical lesions co-expressing
Chlamydia T. and HPV.
Since HPV infection of the cervix by itself is not inflammatory, viral (such as
Herpes Simplex Virus, HSV) and bacterial (such as Chlamydia Trachomatis, CT)
infections serve as the main sources of cervical inflammation. Chlamydia Trachomatis is
a well-known cause of the inflammatory condition, cervitis, and cervical cancer cells
infected with Chlamydia Trachomatis secrete higher levels of proinflammatory cytokines
than uninfected cervical cancer cells (Rasmussen et al., 1997). Several recent studies
have determined that co-infection with either CT or HSV is associated with a greater risk
of developing cervical cancer (Finan, Musharrafieh, & Almawi, 2006), and have also
pointed to an association between the development of cervical cancer and other sexually
transmitted infections such as Neisseria gonorrhoeae (Hawes & Kiviat, 2002). In
addition, co-infection of HPV 16 with herpesviruses such as CMV and EBV, as well as
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with HSV2, increased the frequency of HPV-16 integration (Szostek, Zawilinska, Kopec,
& Kosz-Vnenchak, 2009), and Chlamydia Trachomatis infection was shown to favor the
entry and persistence of multiple HR-HPV types in cervical epithelium (Paba et al.,
2008). A paper by Schwebke and Zajackowski reported that it was the inflammation
caused by such infections, rather than the particular infection itself, that was associated
with squamous intraepithelial lesions within the cervix (Hawes & Kiviat, 2002). Infection
induced inflammation has also been shown to increase the risk of other HPV-induced
cancers, such as penile cancer, where infection with genital lichen sclerosis increases the
risk of neoplasia in HPV infected men (Barbagli et al., 2006; Nasca, Innocenzi, & Micali,
2006). The inflammation produced as a result of such co-infections can induce the
generation of ROS, which can in turn contribute to the initiation and progression of
cancers through damage to DNA. Thus, factors that affect the generation of reactive
oxygen species, such as smoking and inflammation, may cause DNA damage and affect
HPV integration. As such, they may share a common mechanism in inducing severe
neoplasia.

Reactive Oxygen Species (ROS) in Cells
Reactive oxygen species (ROS) and antioxidants exist in a delicate balance in
cells. Oxidative stress occurs when this balance is disrupted due to either an increase in
the ROS levels in cells, a decrease in the antioxidant levels, or both (Sies, 1997b). Free
radicals play a well-known role in the initiation and promotion of carcinogenesis. They
are molecules that contain one or more unpaired electrons, which allow them to be very
reactive. They are capable of activating pro-carcinogens, altering the level of cellular
antioxidant enzymes, and causing damage to DNA and other biomolecules (Sun, 1990).
15

In turn, antioxidants scavenge the free radicals that cause damage to DNA and other
molecules, and in cases where free radicals are increased over normal levels, cells can
respond by increasing antioxidant synthesis (Valko, Rhodes, Moncol, Izakovic, & Mazur,
2006b). Endogenous ROS originates from the mitochondria, cytochrome P450
metabolism, peroxisomes, and inflammatory cell activation (Inoue et al., 2003). Among
these, the mitochondria are the primary source of the free radicals hydrogen peroxide and
superoxide in cells. Since mitochondrial oxidative phosphorylation is the major source of
free radical generation, mitochondria are enriched with antioxidant enzymes such as
superoxide dismutase (SOD) and glutathione peroxidase (Gpx) (Cadenas & Davies,
2000; F. M. Yakes & VanHouten, 1997). During the process of oxidative
phosphorylation, oxygen is reduced to water in a four-step addition of electrons (Breen &
Murphy, 1995), and in some cases, intermediates escape (see Figure 3). These can
include the superoxide radical, which is then converted to the hydrogen peroxide radical
by superoxide dismutase. The hydrogen peroxide is reduced to water and molecular
oxygen by glutathione peroxidase. Hydrogen peroxide can also be converted via the
Fenton reaction to the highly reactive and dangerous hydroxyl radical (Breen & Murphy,
1995).
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High levels of oxidative stress have been demonstrated the ability to induce
damage to DNA (Kawanishi, Hiraku, & Oikawa, 2001). The highly reactive hydroxyl
radical interacts with DNA, damaging both purine and pyrimidine bases (Dizdaroglu,
Jaruga, Birincioglu, & Rodriguez, 2002). The reaction of the hydroxyl ion with guanine,
the most easily oxidized base, leads to formation of the most common base modification,
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) (Kawanishi et al., 2001; Steenken &
Jovanovic, 1997). ROS-induced DNA damage results in single and double strand breaks,
abasic sites, modified bases and DNA cross-linking (Demple & Harrison, 1994; Marnett,
2000). This damage to DNA leads to mutagenesis and in some cases, to cancer.
In cancer, the antioxidant capacity of cells is frequently diminished. Tumor cells
have been shown to be generally low in manganese superoxide dismutase activity,
usually low in copper and zinc superoxide dismutase activity, and almost always low in
catalase activity (Valko, Rhodes, Moncol, Izakovic, & Mazur, 2006a). The activity of
glutathione peroxidase and glutathione reductase is highly variable in these cells (Sun,
1990). It is possible that these factors contribute to the high levels of oxidative stress
normally observed in tumor cells.

Oxidative Stress in Viral Infections
The occurrence of oxidative stress during a viral infection is an established
phenomenon and has been demonstrated in several viral infections including human
immunodeficiency virus (HIV), hepatitis B virus (HBV) and influenza (K. B. Schwarz,
1996). As a result, there is increased interest in understanding the role of oxidative stress
in the pathogenesis of viral infection. Viral infection is known to induce overproduction
of reactive oxygen species (ROS), nitric oxide, superoxide and their reaction product,
18

peroxynititrite, all of which contribute to oxidative stress (Akaike et al., 1990). Apart
from the increased generation of reactive oxygen species in cells, viral infection can also
increase oxidative stress by decreasing the antioxidant levels in these cells. In mice
infected with influenza A, for example, there is a decrease in the total glutathione and
Vitamin C levels, which in turn causes increased oxidative stress in the cells (Hennet,
Peterhans, & Stocker, 1992). Work done by van Pelt et al has demonstrated that HBV
replication can modulate host gene expression and induce oxidative stress in infected
cells (Severi et al., 2006). Research by Hagen et al demonstrated that mice infected with
hepatitis B demonstrated an increase in oxidative DNA damage in the preneoplastic foci
of the liver (Hagen et al., 1994). Zhang et al demonstrated that in hepatitis B infection,
oxidative DNA damage was caused by an increase in oxidative stress, thus increasing the
frequency of viral integration (Petersen, Dandri, Burkle, Zhang, & Rogler, 1997). In host
cells for hepadnavirus, it has also been shown that viral DNA integration can be
mutagenic, increasing the risk of cancer in their host (Popper, Shafritz, & Hoofnagle,
1987). Consequently, it has been suggested that viral genes may induce oxidative stress
leading to DNA damage (Maura Dandri et al., 2002).
One method that can be used by the cell to counteract the oxidative stress
resulting from viral infection is to increase expression of the cell’s antioxidant enzymes.
The three main classes of antioxidant enzymes are superoxide dismutase, catalase and
glutathione (GSH) peroxidase (Sies, 1997b). In the case of human influenza A virus
infection, increased mRNA expression of the antioxidants Mn-superoxide dismutase
(SOD2) and indoleamine 2,3-dioxygenase was observed (Kathleen B. Schwarz, 1996).
Roederer et al showed that while HIV infection is associated with decreased levels of
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glutathione and cysteine, there is an increase in catalase levels, which may partially
compensate for the decreased levels of the other two antioxidants (M. Roederer, Ela,
Staal, Herzenberg, & Herzenberg, 1992; Mario Roederer, Staal, Osada, Herzenberg, &
Herzenberg, 1991). Since oxidative stress is caused by an imbalance of cellular oxidants
and antioxidants, it is possible that its effect can be alleviated by the administration of
exogenous antioxidants. Antioxidants are known to inhibit viral replication and reduce
virus induced oxidant injury. In fact, N-acetylcysteine, an antioxidant, has been shown to
inhibit HIV replication and apoptosis in vitro (Newman, Balcewicz-Sablinska,
Guarnaccia, Remold, & Silberstein, 1994). Antioxidants can also decrease the long-term
effects of chronic oxidative stress, a occurrence that has been linked to the progression to
cancer (Peterhans, 1997).

Model for Inflammation Induced HPV Integration in Cells
Based on the evidence presented, we propose a scheme for the involvement of
inflammation in HPV carcinogenesis in Figure 4. Approximately 80% of women will be
exposed to HPV within their lifetime. In the majority of these cases, the infection will
spontaneously clear. On occasion, CIN1 lesions will develop, but most of these lesions
will also spontaneously clear. However, in some cases, HPV infected women will
develop cervical inflammation caused by co-infection with either a viral or bacterial
agent. Alternatively, inflammation could be caused by other co-factors such as smoking.
This inflammation will facilitate the progression of CIN1 lesions to CIN2 due to the cell
proliferative effects of inflammation combined with the low level expression of the E6
and E7 viral oncogenes from episomal HPV. At the CIN2 stage, the inflammationinduced generation of reactive oxygen and nitrogen species induces DSBs in both the
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viral and host DNA. This allows HPV integration to occur. HPV integration then leads to
disregulated expression of the viral oncogenes E6 and E7, (CIN3) and eventually to
invasive carcinoma (invCA).

21

22

Purpose of This Study
As mentioned previously, HPV infection alone is known not to be a sufficient
cause for the development of disease; other cofactors are necessary. One such cofactor is
likely to be oxidative stress. This is of particular interest to us since oxidative stress can
cause DNA damage. In almost all cases of cervical cancer, the HPV genome is found
incorporated into the host genome, indicating that this is usually a necessary event for the
development of cancer. Oxidative stress in cells would allow for the necessary DNA
damage that facilitates incorporation.
The HPV life cycle and its role in carcinogenesis have been intensively studied
over the last three decades. However, little is known about why high risk strains of HPV
sometimes become incorporated into the host genome or which HPV genes, if any, are
involved in the process of integration. Therefore, to begin to explore these phenomena we
asked the following questions: 1) Does E6 expression affect the level of cellular oxidative
stress in cells, and if so, what is/are the molecular mechanism(s)? 2) Does expression of
either of the E6 isoforms affect the level of DNA damage in cells? The results from this
study will allow us to begin to elucidate the process of high-risk HR-HPV integration, a
critical step in cell transformation.
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CHAPTER TWO
HPV16 E6* INDUCES OXIDATIVE STRESS AND DNA DAMAGE

Running title: E6* induces oxidative stress
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Abstract
High risk types of Human Papillomavirus (HPV) are the causative agents of
virtually all cases of cervical cancer and a significant proportion of other anogenital
cancers, as well as both oral and pharyngeal cancers. The high-risk types encode two
viral oncogenes, E6 and E7, which work together to initiate cell transformation. Multiple
steps, involving the activities and interactions of both viral and cellular proteins, are
involved in the progression from HPV infection to cell transformation to cancer. The E6
oncoprotein is expressed as several isoforms, a full-length variant referred to as E6 and a
few shorter isoforms collectively referred to as E6*. In this study, we found that
expression of E6* increased the level of reactive oxygen species (ROS) in both HPV+
and HPV- cells. This increased oxidative stress led to higher levels of DNA damage, as
assessed by the comet assay, quantification of 8-oxo-G, and PARP expression. The
observed increase in ROS may be due to a decrease in cellular anti-oxidant activity, as we
found that E6* expression also led to decreased expression of SOD2 and Gpx. These
studies indicate that E6* may play an important role in virus-induced mutagenesis by
increasing oxidative stress and DNA damage.
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Introduction
High risk types of Human Papillomavirus (HR HPV) are the causative agents of
virtually all cases of cervical cancer as well as a significant percentage of other
anogenital and oropharyngeal cancers. In fact, current estimates indicate that HPV
infection may be associated with as many as 93% of anal cancers, 63% of oropharyngeal
cancers, 40% of penile cancers, 64% of vaginal cancers and 51% of vulvar cancers
(Parkin & Bray, 2006). HPV infection accounted for approximately 26,700 cases of
HPV-related cancers in the US (Gargano et al., 2012; Steinau et al., 2013), and it is
estimated that 5.2% of all cancers worldwide can be attributed to HPV infection (Parkin,
2006). While the incidence of cervical cancer has declined in the last 30 years due to PAP
smear screening, the incidence rates of anal, oropharyngeal and vulvar cancers has
steadily increased within that same period (Parkin & Bray, 2006). These numbers
underscore the need for ongoing research into the mechanisms behind HPV-related
carcinogenesis.
The high-risk types of HPV encode two viral oncogenes, E6 and E7, that together
serve as the major initiators of cell transformation (Munger et al., 2004). Multiple steps
are involved in the progression from HPV infection to cellular transformation to cancer.
Virus-related factors influencing this progression include virus persistence, viral load,
and the re-programming of target cell function by HPV early genes to favor virus
production. In rare cases, infection plus subsequent events can lead to HPV genome
integration. The significance of viral genome integration in HPV mediated carcinogenesis
is illustrated by the fact that most cases of HPV-mediated cervical cancer present with the
genome in an integrated form (zur Hausen, 2002). Frequently, this integration allows for
the unregulated expression of the viral oncogenes E6 and E7 (Munger et al., 2004).
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In addition to these virus-related factors, genetic susceptibility to viral infection,
increasing age of the host, and other epigenetic and lifestyle factors such as smoking,
chronic inflammation and co-infection with other STDs, particularly Chlamydia
trachomatis, have been shown to increase the risk of progression to cervical cancer in
HPV infected women (Gravitt Pe, 2001). Several of these factors can be logically linked
to increased oxidative stress and DNA damage. Extensive DNA damage usually leads to
apoptosis (Kaina, 2003), but in cells infected with HPV, the viral oncogenes E6 and E7
rescue cells from this pathway, resulting in mutagenesis, increased cell proliferation and
in rare instances, cancer (C. A. Moody & L. A. Laimins, 2010). One of the factors shown
to promote cellular transformation is oxidative stress. Oxidative stress during viral
infection can be a result of the immune response to viral proteins and/or a consequence of
viral gene expression. Oxidative stress causes oxidative DNA damage which may
facilitate HPV-DNA integration (Williams, Filippova, Soto, & Duerksen-Hughes, 2011).
A link between virus induced oxidative stress and viral pathogenesis has been
demonstrated in several viral infections, including Epstein Barr Virus (EBV), Hepatitis C
virus (HCV) and Hepatitis B virus (HBV). For example, in the case of HBV associated
hepatocellular cancer, it has been shown that the accumulation of HBV mutant surface
proteins in the endoplasmic reticulum of infected cells induces oxidative DNA damage in
the late stages of infection. In HCV induced hepatocarcinogenesis, chronic infection with
HCV is characterized by increased oxidative stress. In the case of EBV and
nasopharyngeal cancer, the lytic life cycle and the viral oncogene EBNA-1 have both
been shown to induce oxidative stress (Hsieh et al., 2004; Kamranvar & Masucci, 2011;
Ma et al., 2008; Taylor, Raghuwanshi, Rowe, Wadowsky, & Rosendorff, 2011; Tsai &
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Chung, 2010). In these cases, an increase in oxidative stress both causes direct oxidative
DNA damage, and also participates in various signaling pathways that can lead to
chromosomal aberrations and cell transformation.
In the case of HPV infection, the host immune response is generally limited and
viral infection itself does not induce a state of chronic inflammation. The primary reason
for this is that the virus infects basal epithelial cells, which are shielded from circulating
immune cells during the initial stages of infection. Nevertheless, reactive oxygen species
(ROS) and reactive nitrogen species (RNS) have potential significance to the
development of viral carcinogenesis. For example, one study showed that exposing cells
infected with HPV 16 to the reactive nitrogen species nitric oxide increased the levels of
E6 and E7 and increased the level of DNA damage (Wei, Gravitt, Song, Maldonado, &
Ozbun, 2009). Also, previous research has shown that the expression of HPV 16 E6 in
L929 cells increases ROS accumulation (Liu, Tergaonkar, Krishna, & Androphy, 1999).
HPV16 E6 is expressed in cells as two main isoforms, a full-length variant (E6)
and a few similarly truncated variants frequently referred to collectively as E6* due to
their similarity. The function and activities of the full-length oncoprotein, E6, have been
intensively studied over the last two decades (Howie, Katzenellenbogen, & Galloway,
2009; C. A. Moody & L. A. Laimins, 2010; S. S. Tungteakkhun & P. J. DuerksenHughes, 2008). In contrast, relatively little is known regarding the activities of the
truncated E6* isoform, and its significance in both the viral life cycle and in
carcinogenesis has been disputed. The early transcripts produced from the early promoter
located upstream of the E6 gene can undergo alternative splicing from a donor site
located within the E6 gene (nucleotide (nt) 226 in the case of HPV16) to an acceptor site
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that can be located either within or outside of the E6 gene. This results in the production
of several E6* splice variants. This splicing pattern is a unique characteristic of all highrisk HPV types, and is not restricted to HPV 16 and HPV 18. Rather, it is also present in
the high-risk types HPV 31, HPV 33, and HPV 45, which together with HPV 16 and 18
are responsible for almost all cases of cervical cancer. Interestingly, E6* is the most
abundant splice variant produced during the early stages of infection (Heer, Alonso, & de
Prat-Gay, 2011). In contrast, low-risk types do not express E6* due to the absence of the
consensus splice site. Work done in both our laboratory and that of Dr. Banks suggests
significant and independent roles for the E6* splice variant. For instance, we observed
that over-expression of E6* in SiHa cells sensitized these cells to both TNF- and Fasinduced apoptosis (Maria Filippova et al., 2009b), and that full-length E6 and E6* bind to
different regions on procaspase 8 and have opposite effects on the stability of that protein
(Tungteakkhun, Filippova, Fodor, & Duerksen-Hughes, 2010). Work done by the Banks
group has shown that HPV18 E6* regulates the ability of the full-length isoform to
degrade p53, with an inverse relationship between the level of E6* and the ability of fulllength E6 to degrade p53 (Pim & Banks, 1999). This group has also shown that E6* can
suppress the growth of transformed cells (D. Pim, P. Massimi, & L. Banks, 1997). Taken
together, these observations suggest that E6* possesses important and distinct functions
from the full-length isoform of E6.
In the current study, we discovered that E6*, but not E6, increases cellular ROS
and leads to higher levels of DNA damage. Modulation of the ratio of E6 isoforms can
change these ROS levels, with increased proportions of E6* consistently promoting
oxidative stress. We also investigated the mechanisms responsible for these changes, and
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found that the truncated versions of E6 may modulate the expression of enzymes
involved in ROS metabolism, thereby leading to higher levels of ROS and DNA damage.

Materials and Methods
Reagents
Monoclonal α-SOD1 and α-Glutathione peroxidase were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Monoclonal -SOD2 was obtained from BD
Biosciences (Franklin Lakes, NJ), and monoclonal α-PARP 1 was purchased from
Calbiochem (Billerica, MA). Monoclonal -β-actin was obtained from Sigma-Aldrich (St.
Louis, MO). Monoclonal antibodies directed against the HPV16 E6 N-terminus were
obtained from Euromedex (France). MG132 was purchased from Sigma-Aldrich (St.
Louis, MO).
Cell Culture
CaSki and SiHa cells (derived from human cervical carcinomas), L929 (mouse
fibrosarcoma) and U2OS (human osteosarcoma) cells were obtained from the ATCC
(Manassas, VA). CaSki, SiHa cells and L929 cells were cultured in modified Eagle
medium (MEM) (CellGro, Manassas, VA), U2OS was cultured in McCoy’s 5a Medium
Modified, and normal oral keratinocyte (NOK) cells were grown in Keratinocyte Serum
Free Medium (Invitrogen, Carlsbad, CA). The medium for all cells was supplemented
with penicillin (100 u/ml) and streptomycin (100 µg/ml) (Sigma-Aldrich, St. Louis, MO).
MEM and McCoy 5a were supplemented with 10% FBS (Invitrogen, Carlsbad, CA).

Plasmids, siRNA Inhibition and Transfections
Plasmids pFlag-E6 and pFlag-E6* were obtained by cloning E6 and E6* in frame
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with the N-terminal Flag-tag and the C-terminal C-myc-tag into the pFlag-myc CMV-22
vector (Sigma-Aldrich, St. Louis, MO). Cloning of Flag-E6* and Flag-E6 into the
retroviral vector pLNCX (BD Clontech, Mountain View, CA) and production of
retroviral stocks have been described previously (Filippova et al 2009). To inhibit the
expression of E6, target sequences for shE6, as well as the scrambled sequence, were
cloned into pSilencer 3.1 (Invitrogen, Carlsbad, CA) (Filippova et al, 2009).
Transfections were carried out using the TransIT®-2020 Reagent (Mirus Bio,
Madison, WI), as directed by the manufacturer. For transient transfections, cells were
analyzed 48 h post-transfection. SiHa- and CaSki-derived stable cell lines were obtained
by transfection of the parental cells with the corresponding plasmids, followed by G418
or puromycin selection for 2 to 3 weeks. NOK-derived stable cell lines were produced by
transduction of retrovirus pLNCX, pLNCX-E6* or pLNCX-E6, followed by isolation of
clones derived from single cells. Individual clones were selected, grown and analyzed for
protein expression by immunoblotting and/or RT-PCR.
Expression of SOD2 in NOK cells was decreased by siRNA inhibition, employing
the siControl and siSOD2 oligos obtained from Invitrogen (Grand Island, New York). XtremeGENE siRNA transfection reagent (Roche Diagnostics, Mannheim Germany) was
used to transfect these cells with the siControl and siSOD2 siRNA oligos according to the
manufacturer’s protocol.

Measurement of ROS by Flow Cytometry
Cellular levels of hydrogen peroxide, hydroxyl and peroxyl radicals (H2O2, OHand ROO-) and superoxide (O2−) were estimated using 5-(and-6)-Carboxy-2',7'-
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Dichlorodihydrofluorescein Diacetate (DCF) or Dihydroethidium (DHE), respectively
(Peshavariya, Dusting, & Selemidis, 2007). All fluorescent probes were purchased from
Invitrogen (Carlsbad, CA). 20 mM stock solutions were diluted into culture media, and
added to cells to a final concentration of 10 µM DCF and 5 µM DHE. Cells were
incubated at 37ºC in the dark for 25-30 minutes. After treatment, cells were trypsinized,
washed and collected in PBS. Cells were analyzed using the Becton-Dickinson
FACSCalibur flow cytometer (BD, Franklin Lakes, NJ). A total of 10,000 events were
measured per sample. DCF was detected in the FL-1 channel (530/30 nm), while DHE
was detected in the FL-2 channel (650 nm). Data was collected in log scale and analyzed
using Cell Quest Pro and Flow-Jo software.

Immunoblotting and Immunoprecipitation
For immunoblot analysis, 106 of the indicated cells were lysed in 200 µl Laemmli
Lysis Buffer, and lysates were separated by SDS-PAGE. After transfer of protein onto
Immobilon P membranes (Millipore, Billerica, MA) and blocking of the membrane with
1% BSA, primary antibodies, diluted in Tris-buffered saline-Tween-20 (TBST) were
applied. After incubation at 40C overnight, membranes were washed with TBST and
secondary ImmunoPure antibody ( -mouse or -rabbit) conjugated with HRP (Thermo
Scientific) was applied. Signal was detected using the chemiluminescent SuperSignal
West Femto or Pico maximum-sensitivity substrate (Thermo Scientific, Rockford, IL).
For detection of the E6 isoforms in SiHa pSilencer, SiHa siE6, SiHa pFlag and SiHa
pE6* cells, 106 cells were pretreated with 10 μM MG132 16 h prior to preparation of the
lysates. The cells were collected and lysed in 100 μl of RIPA buffer (Sigma-Aldrich).
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For immunoprecipitation, 107 cells from each of the NOK clones, NOK pLNCX
and NOK pLNCX-E6, were treated with 10 μM MG132 for 16 h prior to preparation of
lysates. Flag-tagged proteins were then precipitated using Flag-agarose, and bound
proteins were subjected to SDS-PAGE, then transferred to a PVDF membrane and
detected by immunoblot. Detection of Flag-E6* and Flag-E6 were performed using αFlag-HRP antibodies.

Comet Assay
The comet assay was performed using the Trevigen Kit (Trevigen, Gaithersburg,
MD) under alkaline conditions. Nuclei were stained with SYBR® GOLD (Invitrogen,
Carlsbad, CA). For each sample tested, 100 DNA tails were photographed and analyzed.
The length of each tail was measured from the center of the comet to the end of the tail
using Image J software, and each tail was categorized into one of four tail types reflecting
the severity of DNA damage. DNA damage was classified into four classes of tail lengths
(0-50, undamaged; 50-100, minimum damage; 100-150, medium damage; >150,
maximum damage) such that the severity of DNA damage increases proportionately with
tail length.

8-Oxyguanine DNA Damage Analysis
DNA damage was determined by binding the FITC conjugate to 8-oxodeoxyguanosine (8-oxodG). Cells were fixed in 1% paraformaldehyde and permeabilized
in methanol. After fixation and permeabilization, cells were washed, blocked, and
incubated with OxyDNA FITC conjugate (Calbiochem, San Diego, CA) for 1 hour in the
dark. Cells were resuspended in PBS and analyzed by flow cytometry for fluorescence
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(excitation 495 nm, emission 515 nm) on the BD FACS Calibur (BD, Franklin Lakes,
NJ). Data was analyzed using the Flow-Jo software. A total of 10,000 events were
measured per sample.

RNA Isolation and RT-PCR
Cells were plated in a 10 cm tissue culture plate and allowed to grow to 80
percent confluency. RNA was isolated using Tri Reagent according to the manufacturer’s
protocol (Sigma Aldrich, St. Louis, MO). cDNA was synthesized using ImPromII reverse
transcriptase (Promega, Madison, WI) and an oligo(dT) primer. Primers for the 5’ and 3’
ends of Flag (5’ ATGGGCGGTAGGCGTGTAC 3’ and 5’ GGTCACAGGGATGCCAC
3’) were used to amplify PCR products for the E6 full length and splice variants
expressed from plasmids. Primers for the 5’ and 3’ ends of E6 (5’
AATGTTTCAGGACCCACAGG 3’ and 5’ CACACAACGGTTTGTTGTATTGCTG
3’) were used to amplify PCR products for the E6 full length. The E6* splice variant was
amplified using the same primer for the 5’ end with a different primer for the 3’ end (5’
CTTTTGACAGTTAATACACCTCACG 3’) (Hafner et al., 2008). The PCR product
from PGK1, using primers 5’ CTGTGGGGGTATTTGAATGG 3’ and 5’
CTCCAGGAGCTCCAAACTG 3’ was used for normalization.

qRT-PCR
Quantitative real-time PCR (qRT-PCR) to measure the levels of the E6 isoforms
was conducted using primers designed as described previously by Hafner et al. (Hafner et
al., 2008) along with the Absolute QPCR Sybr green kit according to the manufacturer’s
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protocol (Bio-Rad Laboratories, Inc.). Observed E6 isoform concentrations were
normalized using the level of β-actin or 36B4 expression.

Statistics
All assays were repeated at least three times. Results are reported as mean ± s.d.
Differences were analyzed by Student’s t-test. P<0.05 was regarded as significant.

Results
ROS Levels are Higher in CaSki than in SiHa Cells
Our initial studies examining the influence of E6 and E6* on ROS levels were
done using CaSki and SiHa cells, which are well-known cellular models of cervical
cancer derived from HPV 16+ cervical carcinomas. ROS levels in SiHa and CaSki cells
were estimated using flow cytometry following staining with the fluorescent dyes 5-(and6)-carboxy-2',7'-dichlorofluorescein diacetate (DCF) (detects hydrogen peroxide,
hydroxyl and peroxyl redicals) and dihydroethidium (DHE) (Peshavariya et al., 2007)
(detects superoxide radicals). The flow cytometry results clearly demonstrated that the
levels of both species were higher in CaSki cells than in SiHa cells (Figure 1A).These
results were repeated three times to generate the bar graphs shown in Figures 1B and 1C.
Because previous studies suggested that E6 may be responsible for the increase in ROS
(Liu et al., 1999), we postulated that the difference in ROS levels between these cell lines
might be due to differences in E6 expression. Interestingly, the level of expression of full
length E6 was similar in both cell lines, while the level of expression of E6*I (M.
Filippova et al., 2014), the most abundant splice product (referred to as E6* from this
point forward) was much higher in CaSki than in SiHa cells (Figure 1D and 1E). These
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findings are consistent with results we obtained earlier concerning the ratio between E6
and E6* protein levels (Maria Filippova et al., 2009a). Since both the ratio of E6*/E6
expression and the absolute level of E6* expression differ between these cell lines, it was
possible that either or both factors could contribute to the elevated ROS levels.
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Increased E6*/E6 Ratios Cause Higher Levels of ROS in SiHa Cells
If a difference in the ratio between E6 isoforms was the major factor determining
the difference in ROS levels, one resulting prediction is that changing the ratio between
E6 and E6* should alter the level of ROS. To test this idea, we decreased E6 expression
in SiHa cells such that the ratio of E6*/E6 would increase. We designed shRNA to target
E6 and cloned it into the pSilencer vector, then stably transfected either the empty vector
or pshE6 into SiHa cells to generate the SiHa pSilencer control cell line and the stable
cell line SiHa shE6, respectively . qRT-PCR analysis (Figure 2A) and immunoblot data
(Figure 2B) both showed that E6 expression was indeed decreased in these cells. Figure
2C shows the bar graph generated following staining of these SiHa-derived cells with
DCF, demonstrating that increasing the relative ratio of E6*/E6 expression in SiHa cells
led to a parallel increase in the level of ROS as compared to the control cell line SiHa
pSilencer.
To further evaluate the possibility that differences in the E6*/E6 ratio may affect
ROS levels, we also manipulated the ratio of E6 isoform expression by increasing the
relative amount of E6* in SiHa cells. E6* was cloned into the pFlag vector in frame with
the Flag tag at the N-terminus and C-myc at the C-terminus, and stable cell lines
expressing the vector-derived E6* were produced. To eliminate the effect of clonal
integration, six clones with the highest level of E6* expression were combined to produce
SiHa pE6* pooled cells. These cells, together with SiHa pFlag control cells, were stained
with DCF and analyzed by flow cytometry. DCF staining was carried out in triplicate to
produce the bar graph shown in Figure 2F. The results clearly demonstrate that the SiHa
pE6* pooled cell line displayed higher levels of ROS than did control cells transfected
with the empty vector. Thus, over-expression of the E6* isoform in SiHa cells was able
38

to further increase ROS levels in these cells. qRT-PCR analysis and immunoblot data
(Figures 2D and 2E respectively) confirmed the higher level of E6* expression in SiHa
pE6* cells as compared to vector control cells.
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Over-expression of E6*, But Not of Full Length E6, Increases ROS
Levels in Cells
The experiments described above demonstrate that manipulating E6 isoform
levels so that the E6*/E6 ratio increased also increased ROS levels. However, in these
experiments, both isoforms were present, potentially complicating interpretation. To
address this limitation, we individually expressed E6 and E6* in the HPV-, non-cervical
cancer cell lines U2OS (human osteosarcoma) and L929 (mouse fibrosarcoma). Cells
were transiently transfected with the pFlag plasmid coding for E6, E6* or the empty
vector (control). Forty-eight hours post-transfection, these cells were stained with DCF
for ROS analysis using the fluorimetric plate reader. In both U2OS- and L929- derived
cell lines, ROS levels were increased in cells expressing pE6* as compared to those
expressing the vector control or pE6 (Figure 3A and 3C respectively). Figures 3B and 3D
show RT-PCR data confirming the expression of E6L and E6* in U2OS and L929 cells
respectively. These findings indicate that the actual level of E6* expression is responsible
for the increase of ROS levels in cells, and also that the effect of E6* on ROS levels is
independent of the presence or absence of other HPV proteins.
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ROS Levels are Higher in NOK Cells Expressing E6*
The findings discussed above were demonstrated in transformed cancer cells. To
ask whether the activities of full-length E6 and/or E6* might contribute to differences in
cellular ROS in non-transformed target cells, the influence of each isoform on ROS levels
was investigated individually in immortalized non-transformed normal oral keratinocytes
(NOK). These cells were chosen because they are natural targets of HPV infection and
can be transformed by HPV 16 (Park, Min, Li, Huang, & Doniger, 1991).
The E6* and full-length E6 isoforms tagged with the Flag epitope were cloned
into the pLNCX retroviral vector. NOK immortalized by hTert expression (Piboonniyom
et al., 2003) were then infected with the retroviral stocks (pLNCX (control), pLNCX-E6*
and pLNCX-E6), and several stable cell lines were obtained for each isoform. The level
of ROS was measured in 2 cell lines expressing pLNCX-E6* (1and 5) and in 2 cell lines
expressing pLNCX-E6 (1 and 3), and compared to that seen in control pLNCX cells.
Figure 4A shows the flow cytometry results following DCFDA staining in these cells.
Figure 4B shows PCR data confirming the expression of E6L and E6* in the NOK stable
cell lines. Representative cell lines (NOK pLNCX, NOK pE6* 1 and NOK pE6 5) were
chosen, and the experiment was then repeated three times following DCF and DHE
staining to generate the bar graphs shown in Figure 4C. qRT-PCR data (Figure 4D) and
immunoblot (Figure 4E) confirmed the higher level of E6 isoform expression in the
selected NOK clones. Overall, NOK cells expressing E6* displayed higher levels of ROS
compared to NOK cells expressing the empty vector pLNCX. In contrast, NOK cells
expressing the full-length isoform demonstrated no significant change relative to control
cells.
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Superoxide Dismutase and Glutathione Expression Levels Decrease
with E6* Expression
A number of factors may contribute to the observed increase in cellular ROS
following E6* expression. One possibility is that E6*-expressing cells possess a reduced
antioxidant capacity, thereby allowing ROS levels to increase due to the cell’s reduced
ability to adequately dispose of them. To determine whether decreases in the cellular
antioxidant capacity might contribute to E6*-mediated increases in ROS, we examined
the expression of two important antioxidant enzymes, superoxide dismutase (SOD) and
glutathione peroxidase (Gpx). SOD can be expressed as three isoforms, SOD1, SOD2
and SOD3. Of the three, only SOD1 and SOD2 are intracellular, and were therefore
chosen for analysis.
We observed that SiHa and CaSki cells differed not only in ROS but also in the
levels of expression of antioxidant proteins (Figure 5A). In particular, ROS levels are
higher, while expression of the antioxidant enzymes SOD2 and Gpx1/2 was lower in
CaSki as compared to SiHa cells. To further investigate the relationship between
antioxidant expression levels and E6 isoform expression, we repeated these experiments
in the NOK system. Consistent with our findings in the cervical cancer cell lines, we
observed a distinct reduction in SOD2 expression in NOK pLNCX-E6* cells as
compared to the control (NOK pLNCX), while no change was detected in SOD 1 levels.
Furthermore, NOK cells expressing E6* displayed lower levels of Gpx expression
(Figure 5B). In contrast, NOK cells expressing the full-length isoform, pLNCX-E6, did
not display significantly changed levels of these proteins. The data described above
suggests that E6* may have the ability to affect the levels of SOD2 and/or Gpx 1/2 and
that this in turn affects the levels of ROS in these cells. To further explore this possibility,
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we asked whether decreases in the expression of antioxidant enzymes such as SOD2,
would also lead to increased ROS levels in NOK cells. NOK cells were transiently
transformed with either siControl or siSOD2 siRNA for 72 h. Cells were then collected,
and either stained with DCF to detect ROS or used to prepare protein lysates for the
detection of SOD2 levels. Figure 5C demonstrates a decrease in SOD2 expression in
siSOD2 NOK cells compared to siControl, and Figure 5D shows that this decrease in
SOD2 resulted in an increase in ROS levels in NOK siSOD2 cells. Together, these
findings support the idea that lower expression of antioxidant proteins may contribute to
the higher ROS levels observed in E6*-expressing cells.
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E6* Expression Results in Higher Levels of DNA Damage in Both
Cervical and NOK Cell Lines
The results described above demonstrate that E6* expression leads to an increase
in ROS and a decrease in the level of at least two antioxidant enzymes, SOD2 and GPX.
Both findings point toward the induction of oxidative stress as a result of E6* expression.
Oxidative stress, in turn, is known to induce DNA damage. To determine whether E6*
expression also increases DNA damage, we employed two assays: the comet assay
(Sigma-Aldrich), which detects single strand DNA breaks, and the flow cytometric
OxyDNA assay (Calbiochem), which measures the levels of 8-oxoguanine, one of the
most common oxidative stress base modifications in cells (Grollman & Moriya, 1993).
Figure 6A (upper panel) demonstrates the effect of incremental increases in DNA
damage on comet appearance in control cells following alkaline electrophoresis. The
lower panel shows a representative comet assay performed on NOK cells transfected with
the empty vector, E6* or E6. When CaSki and SiHa cells were analyzed using the comet
assay, the results (Figure 6B), showed that CaSki cells, with their higher level of
oxidative stress, sustained a higher level of DNA damage than did SiHa cells. This is
consistent with a model in which the observed increase in oxidative stress corresponds to
downstream changes in the level of DNA damage. An alternative method of determining
DNA damage is to assess the levels of 8-oxoguanine, since this is the most commonly
modified base. The OxyDNA assay results for the cervical cancer cells CaSki and SiHa
(Figure 6C) reflected the results of the comet assay, namely, that CaSki cells exhibited a
higher level of DNA damage than did the SiHa cells.
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To determine whether increased E6* expression can also lead to DNA damage in
non-transformed cells, comet and OxyDNA assays were performed on the NOK pLNCX,
NOK pLNCX-E6*, and NOK pLNCX-E6 cell lines. We observed (Figures 6D and 6E)
that for both assays, pLNCX-E6* cells displayed a higher level of DNA damage than did
either the control (NOK pLNCX) or the pLNCX-E6 cells. Taken together, these findings
indicate that E6* expression in cells can lead both to increased levels of ROS and to a
corresponding increase in oxidative DNA damage.
Poly [ADP-ribose] polymerase 1 (PARP) is an enzyme that ADP-ribosylates
nuclear proteins and is involved in the repair of DNA breaks. Therefore, we used it as an
indirect marker of DNA damage to validate our findings (Huber, Bai, de Murcia, & de
Murcia, 2004). Our data revealed higher levels of PARP1 expression in CaSki (Figure
7A) than in SiHa, and in NOK pLNCX-E6* cells compared to NOK pLNCX or NOK
pLNCX-E6 cells.
If E6* causes oxidative damage leading to DNA damage, we would predict that
over-expression of E6* in SiHa cells would result in an increase in DNA damage.
Analyzing the levels of 8-oxoguanine in SiHa pE6* as compared to SiHa pFlag control
cells confirmed this expectation (Figure 7C). Consistent with these findings, SOD2 levels
were lower in the SiHa pE6* cells than in the SiHa pFlag control cells (Figure 7D).
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Discussion
In this study, we demonstrated that expression of E6*, the truncated splice variant
of the HPV 16 E6 protein, can increase ROS levels in host cells. This may be due to
decreased expression of anti-oxidant enzymes, and leads to downstream DNA damage.
The generation of oxidative stress during a viral infection is a common occurrence during
the inflammatory response to infection, due to the release of ROS from neutrophils and
macrophages during the “oxidative burst”. In addition, activated phagocytes release prooxidant cytokines. RNA viruses such as influenza A and members of the
paramyoxoviridae family have been shown to activate monocytes and
polymorphonuclear leukocytes, which respond to infection with a respiratory burst and
generate ROS. However, some viruses such as HPV, EBV and HBV are weakly
immunogenic, and do not necessarily induce a pronounced inflammatory response
(Levitsky & Masucci, 2002; Tindle, 2002; Wieland & Chisari, 2005). Interestingly,
oxidative stress plays a significant role in viral pathogenesis in these infections as well.
Several groups have demonstrated that HBV can induce oxidative stress both in vivo in
mice in and in vitro in cells (Ha, Shin, Feitelson, & Yu, 2010). The Human hepatitis virus
x protein targets the mitochondria to alter membrane potential and increase endogenous
ROS levels, while HBV infected cells carrying the HBV pre-S mutant exhibited
enhanced levels of ROS and oxidative DNA damage through endoplasmic reticulum
stress pathways (Wang, Huang, Lai, & Su, 2006). Although the significance of oxidative
stress in the context of the viral life cycle has not been elucidated in each of these cases,
biologically-significant effects of these increases in oxidative stress have been welldocumented.
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E6/E7 mRNA from high-risk HPV types undergoes alternate splicing to produce
an E6* transcript, which is often the most prevalent species found both in cervical tumors
and in the early stages of HPV infection. Here, we present data demonstrating that the
E6* isoform present in high risk HPV types increases oxidative stress in both HPV+
(Figures 1 and 2) and HPV- (Figures 3 and 4) cell lines. In contrast, the full-length
isoform, E6, displayed no significant effect on ROS.
Reactive oxygen species (ROS) and antioxidants exist in a delicate balance in
cells. Oxidative stress occurs when this balance is disrupted due to either an increase in
ROS production, a decrease in cellular antioxidant levels, or both (Sies, 1997b). The
reactive oxygen species released during oxidative stress have the ability to directly
damage DNA. (Kawanishi et al., 2001). One reactive oxygen species in particular, the
highly reactive hydroxyl radical, interacts with DNA directly, damaging both purine and
pyrimidine bases (Dizdaroglu et al., 2002). The reaction of the hydroxyl ion with
guanine, the most easily oxidized base, leads to formation of the most common base
modification, 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) (Kawanishi et al., 2001;
Steenken & Jovanovic, 1997). In addition to creating modified bases, ROS-induced DNA
damage leads to single and double strand breaks, abasic sites and DNA cross-linking
(Demple & Harrison, 1994; Marnett, 2000). This damage to DNA may lead to mutations,
aberrations and genomic rearrangements. Consistent with these observations, our data
shows that DNA damage is highest in HPV+ cells with higher relative E6* expression
(Figure 6B and 6C), as well as in NOK cells expressing E6* (Figure 6D and 6E). PARP,
a cellular marker of DNA damage was also increased in CaSki cells compared to SiHa
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cells, and in NOK E6* compared to NOK pLNCX and NOK pLNCX-E6 cells, further
validating our data showing that DNA damage is higher in these cell lines (Figure 7).
One of the mechanisms by which cells can counteract the effects of increased
oxidative stress is through the expression of antioxidant enzymes. Endogenous ROS
originates from the mitochondria, cytochrome P450 metabolism, peroxisomes, and
inflammatory cell activation (Inoue et al., 2003). Among these, the mitochondria are the
primary source of the free radicals hydrogen peroxide and superoxide in cells. Since
mitochondrial oxidative phosphorylation is the major source of free radical generation,
mitochondria are enriched with antioxidant enzymes such as SOD and Gpx (Cadenas &
Davies, 2000; F. â. M. Yakes & Vanâ€‰Houten, 1997). In this report, we demonstrate
that changes in cellular ROS are associated with changes in the expression of antioxidant
enzymes such as SOD2 and Gpx (Figures 5 and 7D). Events that cause a decrease in
SOD are predicted to result in an increase in the levels of ROS. We found that
expressing E6* in NOK cells resulted in both a decrease in SOD2 expression and a
corresponding increase in ROS (Figures 4 and 5). In addition, CaSki cells displayed
lower levels of SOD2 than did SiHa cells, and these lower levels of SOD2 were
associated with higher levels of ROS (Figures 1 and 5). Gpx also functions in antioxidant
defense, and its inhibition results in an increase in the level of cellular ROS as well
(Valko et al., 2006a). Our findings with Gpx mirror those of SOD2, with an increase in
E6* leading to a decrease in Gpx and an increase in ROS (Figures 1, 4, and 5).
Expression of antioxidant enzymes is regulated by several transcription factors including
AP-1, SP-1, Nf-κB, p53, and NRF2 among others (Dhar, Young, & Colburn, 2002; Surh,
2005). It is possible that E6* may modulate the expression of antioxidant enzymes either
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directly or indirectly by influencing transcriptional factor expression or activity.
However, this question requires further investigation.
In conclusion, we have now demonstrated that expression of the HPV 16 E6*
isoform increases oxidative stress and induces oxidative DNA damage in host cells. The
significance of this increase in ROS to the HPV virus life cycle requires further
exploration. Presently, we can only speculate that this increase in ROS and oxidative
DNA damage may contribute to viral genome production. Recent studies suggest that the
introduction of double strand DNA breaks into HPV DNA during productive replication
is an important step in HPV genome amplification and genome maturation (Gillespie,
Mehta, Laimins, & Moody, 2012). Studies have also shown that exposure of cells that
normally maintain episomal copies of the HPV genome to physiologically high doses of
nitric oxide can lead to up-regulation of early E6 and E7 oncogene expression, as well as
to a significant increase in DNA double strand breaks (Wei et al., 2009). This increased
oxidative stress likely plays a role in HPV-mediated carcinogenesis. For example, studies
in W12 cells demonstrated that increased DNA double-strand breaks are associated with
HPV 16 integration in cervical keratinocytes (D. M. Winder et al., 2007). In addition,
ROS-induced DNA damage results in single and double strand breaks, abasic sites,
modified bases and DNA cross-linking (Demple & Harrison, 1994; Marnett, 2000).
Interestingly, expression of the E6* variant of E6 coincides with E7 expression during the
early stages of HPV infection, and has been demonstrated to be the most prevalent
species in cervical tumors (Heer et al., 2011), suggesting that a clear understanding of its
activities and roles is likely to contribute to our understanding of both the virus life cycle
and to carcinogenesis. With this study, we have now demonstrated a link between E6*

55

expression and oxidative stress in cells, by showing that E6* expression can increase
ROS levels, resulting in increased levels of DNA damage. Further work will focus on the
impact of this E6*-mediated oxidative stress on the virus life cycle and carcinogenesis.
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CHAPTER THREE
IDENTIFICATION OF PATHWAYS INVOLVED IN ROS
REGULATION AND DNA DAMAGE

Introduction
High Risk types of Human Papillomavirus (HPV) are the causative agents of most
cases of cervical cancer as well as a significant proportion of oropharyngeal and other
anogenital cancers. High-risk types of the virus encode two viral oncogenes, E6 and E7,
that respectively are responsible for degrading the cellular proteins p53 and
retinoblastoma (pRB) and for inducing cell transformation (Munger et al., 2004). In HPV
16 and HPV 18, the two types most frequently involved in cervical cancer, these two
viral oncogenes are transcribed as a single bicistronic E6E7 transcript using a common
promoter and a common early polyadenylation site (Tang, Tao, McCoy, & Zheng, 2006).
This bicistronic E6E7 pre-mRNA contains three exons and two introns (Tang et al.,
2006). Intron 1 is positioned in both the HPV 16 E6 and the HPV 18 E6E7 pre-mRNAs,
and is efficiently spliced in these high-risk strains to produce the E6*I spliced transcript
(J. Doorbar et al., 1990; Zheng, Tao, Yamanegi, Bodaghi, & Xiao, 2004). This splicing
pattern appears to be a unique characteristic of all high-risk HPV types, as it is not
confined to HPV 16 and HPV 18. In fact, the high-risk types HPV 16, HPV 18, HPV 31,
HPV 33, and HPV 45, which together are responsible for almost all cases of cervical
cancer, all display the ability to produce these variants. In contrast, the low-risk types
HPV 6 and HPV 11 do not demonstrate this ability (Naucler et al., 2007).
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The function and activities of the full-length E6 isoform have been intensively
studied over the last two decades, and several excellent reviews have been published that
detail its functions and activities (Howie et al., 2009; Cary A. Moody & Laimonis A.
Laimins, 2010; S. Tungteakkhun & P. Duerksen-Hughes, 2008). In contrast,
comparatively little is known of the activities of the E6* isoform, and its significance in
both the viral life cycle and in carcinogenesis has been disputed. However, several sets of
data suggest that the E6* isoform modulates the activity of the full-length E6, and that it
may also possess activities that are independent of E6. For instance, we observed that
overexpression of E6* in SiHa cells sensitized these cells to both TNF and Fas-induced
apoptosis (M. Filippova et al., 2009). We also showed that full-length E6 and E6* bind to
different regions on procaspase 8. E6 large binding leads to accelerated degradation of
procaspase 8, while E6* binding leads to protein stabilization (Tungteakkhun et al.,
2010). Work done by the Banks group has shown that the HPV18 E6* protein regulates
the ability of the full-length isoform to degrade p53, with an inverse relationship
observed between the level of E6* and the ability of full-length E6 to degrade p53. Taken
together, these observations suggest that E6* possesses important and distinct functions
from those of the full-length E6 isoform. A 2014 paper from our lab has also shown
novel independent activities for the E6* isoform. In this report, we demonstrated for the
first time that HPV 16 E6* can increase ROS levels and DNA damage in both HPV
positive and HPV negative cells (Williams, Filippova, Filippov, Payne, & DuerksenHughes, 2014). This ability is anticipated to have potential significance for HPVmediated carcinogenesis, since DNA damage sites may facilitate HPV integration
(Williams et al., 2011).

58

To investigate the pathways involved in ROS regulation that may be influenced
by HPV 16 E6 isoform expression, we employed the cervical cancer cell lines CaSki and
SiHa. We chose these two lines because we had previously demonstrated that they
express significantly different ratios of the E6 splice variants, such that the CaSki cells
have a higher E6*/E6 ratio than do the SiHa cells. This higher E6*/E6 ratio is reflected in
the higher ROS levels observed in CaSki cells (Figure 1). We used these cells to
determine what pathways are likely to contribute to the differences in ROS profiles
observed in these cells by employing a proteomic analysis to identify several pathways in
which protein expression differed significantly between CaSki and SiHa cells. Our
findings revealed that some of the identified pathways were those involved in ROS
regulation. Differential expression of several of the identified proteins was then validated
by immunoblot. To complement this protein-level data, a PCR microarray approach was
employed to identify several genes involved in ROS metabolism that differed in
expression between the two cell lines. We found that expression of pro-oxidant genes
such as OXR1 were down-regulated in SiHa versus CaSki cells, while antioxidant genes
such as SOD2 were up-regulated. Several of these microarray findings were then
validated by RT-PCR. Together, these protein- and gene expression- datasets may
explain the observation that SiHa cells display lower levels of ROS than do CaSki cells.

Results
ROS Levels are Higher in CaSki than in SiHa Cells
Our initial studies exploring the difference in ROS levels in cervical cancer cell
lines were done using CaSki and SiHa cells, which are well-known cellular models of
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cervical cancer derived from HPV 16+ cervical carcinomas. These two cell lines differ in
the ratio of expression of the two E6 isoforms, in that the ratio of E6* expression to E6
full-length expression is significantly higher in CaSki than in SiHa cells (Figure 1A).
This is consistent with our previously published data, where we demonstrated through
quantitative PCR that while the level of expression of full length E6 is similar in both
CaSki and SiHa cell lines, the level of expression of E6* is much higher in CaSki than in
SiHa cells (Williams et al., 2014). We began by estimating the ROS level in SiHa and
CaSki cells. ROS levels in SiHa and CaSki cells were estimated using flow cytometry
following staining with the fluorescent dyes 5-(and-6)-carboxy-2',7'-dichlorofluorescein
diacetate (DCF) (detects hydrogen peroxide, hydroxyl and peroxyl redicals) and
dihydroethidium (DHE) (Peshavariya et al., 2007) (detects superoxide radicals). The flow
cytometry results clearly demonstrated that the levels of both species were higher in
CaSki cells than in SiHa cells (Figure 1B and 1C).
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Proteomic Analysis Identified Differences in Pathways Connected to
p53 Activation, Mitochondrial Function and Oxidative Stress
To identify the pathways responsible for the different ROS profiles observed in
CaSki versus SiHa cells, we performed a comparative proteomic analysis. Identification
and quantification of proteins was done by simultaneously running TMT-labeled
trypsinized CaSki and SiHa lysates through an LTQ-Orbitrap mass spectrometer. The
total number of proteins in which the level of expression between SiHa and CaSki cells
differed by more than 1.5-fold was 430 (data not shown), and the detected range of
differences in protein levels between these cells ranged from -6.0 to 6.9 fold. Seventy-six
of these proteins were found to be up-regulated, while the remaining proteins were downregulated in SiHa cells as compared to CaSki cells.
To gain insight into the functions of these differentially expressed proteins, we
utilized the online IPA analysis (Ingenuity Systems) tool to group them into functionally
related networks and pathways. Figure 2 summarizes 9 of the functions for which protein
expression differs most between these two lines. Some of the more remarkable
differences in protein levels between SiHa and CaSki cells were detected in proteins
involved in mitochondrial functions such as mitochondrial depolarization, swelling of
mitochondria, and the biogenesis of mitochondria (Figure 2). The involvement of the
mitochondria is significant since the Electron Transport Chain (ETC) is found in the
inner mitochondrial membrane. The ETC is the major source of premature leakage of
electrons to oxygen, leading to the formation of superoxide species that can give rise to
other reactive oxygen species and possibly oxidative stress. Another group of pathways
differentially activated between these cell lines is connected to DNA repair and the DNA
damage response (Figure 2). Differences in the expression of proteins involved in

62

mitochondrial status and DNA repair were accompanied by changes in the levels of
proteins involved in the regulation of ROS levels (Figure 2). For example, NAD(P)H
dehydrogenase, quinine 1 (NQO1), peroxiredoxin 2 (PRDX2) and superoxide dismutase
1 (SOD1), which are responsible for inactivation of superoxide radicals, were found in
higher levels in SiHa than in CaSki cells (data not shown).

63

64

Genes Involved in ROS Metabolism and Homeostasis are UpRegulated in SiHa as Compared to CaSki Cells
To further explore the idea that ROS-related genes are expressed differentially
between SiHa and CaSki cells, we employed the Human Oxidative Stress and
Antioxidant Defense PCR Array (SA Biosciences), which profiles the expression of 84
genes related to oxidative stress. We found that several of these genes were up-regulated
in SiHa (as compared to CaSki) cells, and that a few were down-regulated (Table 1).
Genes whose expression was consistently down-regulated in SiHa (relative to CaSki)
cells included aldehyde oxidase 1 (AOX1), NADPH oxidase complex (NCF2), and
oxidation resistance protein (OXR1); these proteins are responsible for the production of
reactive oxygen radicals. To validate the differences identified by the PCR microarray
between these two cell lines with regards to expression of proteins involved in ROS
metabolism, we evaluated the expression levels of a subset of the proteins involved in
antioxidant defense by immunoblot (Figure 3A). Consistent with our PCR microarray and
proteomic data, the immunoblot analysis confirmed higher levels of SOD1, SOD2 and
glutathione peroxidase 1/2 (Gpx1/2) in SiHa cells compared to CaSki cells. A reduced
level of OXR1 expression in SiHa cells as compared to CaSki cells was also confirmed
by immunoblot (Figure 3A). Genes that were up-regulated in SiHa (Table 1) participate
in ROS metabolism in various ways. For example, cytochrome b-245, alpha polypeptide
(CYBA) is a component of mitochondrial Complex III, which is involved in the transfer
of electrons to Complex IV so that water can be formed. Other genes belong to various
antioxidant systems. For example, SODs, GPXs and PRDXs catalyze reactions that
inactivate superoxide radicals (SODs) or H2O2 (GPXs and PRDXs). Semi-quantitative
RT-PCR (Figure 3B) along with quantitative qRT-PCR (Figure 3C) were also used to
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confirm certain results of the PCR array profiles. Overall, our data demonstrated
significant differences between SiHa and CaSki cells with regards to the expression
levels of genes and proteins involved in ROS metabolism and homeostasis. We observed
that antioxidant levels are generally higher in SiHa as compared to CaSki cells while prooxidant levels were lower.. Consistent with these results, PARP1 expression, a marker of
DNA damage caused by oxidative stress, was also detected at a higher level in CaSki
than in SiHa cells as assessed both by proteomic analysis (data not shown) and by
immunoblot analysis (Figure 3A).
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Materials and Methods
Reagents
Monoclonal α-NQO1, α-OXR1 and α-β-actin were obtained from Sigma-Aldrich,
monoclonal α-SOD1 and α-GPX 1/2 from Santa Cruz Biotechnology, monoclonal α SOD2 from BD Biosciences, and monoclonal α-PARP1 (Ab-2) from Millipore
Corporation (Calbiochem). Fetal Bovine Serum (FBS) was obtained from Life
Biosciences.
Cell Culture
CaSki and SiHa cells (derived from human cervical carcinomas) were obtained
from the ATCC (Manassas VA). All cells were cultured in modified Eagle medium
(MEM) (CellGro). The medium was supplemented with 10% fetal bovine serum (Life
Biosciences) and with penicillin (100 u/ml) and streptomycin (100 µg/ml) (SigmaAldrich).
Proteomics Analysis
SiHa and CaSki cells (107) were lysed in RIPA lysis buffer (Sigma-Aldrich) and
sonicated. Cleared lysates were denatured, reduced, and alkylated as recommended by
the TMT Mass Tagging Kit (Thermo Fisher Scientific) protocol. Trypsin was added at a
protein/enzyme ratio of 30:1 by mass, and the digestion was performed at 37°C
overnight. Peptides were labeled with TMT (tandem-mass-tagging) reagents according to
the manufacturer’s protocol in duplicate, and equal amounts of labeled peptides were
combined to obtain one sample, which was separated into 9 fractions by strong cation
exchange chromatography using TopTip columns (PolyLC). Elution was performed with
increasing concentrations of KCl (from 0 to 0.5 M). Eluates were dried using a
SpeedVac, then desalted using C18/hypercarb TopTip columns (PolyLC). Samples from
69

each fraction were run in triplicate on an Orbitrap Pro mass spectrometer that was
coupled with a nanoLC (ThermoFisher), and the spectra obtained were analyzed with
Proteome Discoverer 1.3 software against the Human International Protein Index (IPI)
database. Peptides were identified with a FDR (False Discovery Rate) of less than 1%.
Proteins were considered differentially expressed if the fold ratio was more than 1.5.
Protein data were further analyzed using Ingenuity Pathway Analysis (IPA) software to
identify differences in pathways and networks between cell lines.

Measurement of ROS in Cells by Flow Cytometry
Intracellular generation of hydrogen peroxide (H2O2), hydroxyl and peroxyl
radicals (DCFDA) and superoxide (O2−) (DHE) was estimated using either the 5-(and6)-Carboxy-2',7'-Dichlorodihydrofluorescein diacetate (DCF) or Dihydroethidium (DHE)
membrane permeable probes (Life Biosciences). Reagents were diluted into culture
media, and then added to cells to a final concentration of 10 µM. After treatment, the
cells were collected in 1X PBS and analyzed using the Becton-Dickinson FACSCalibur
flow cytometer (Becton-Dickinson, San Francisco, CA). DCF was detected in the FL-1
channel, while DHE was detected in the FL-2 channel. Data was collected in log scale
and analyzed using Flow-Jo software.

Immunoblot Assays
For immunoblot analysis, 106 cells were lysed in 100 µl of Laemmli lysis buffer,
and lysates were sonicated and separated by SDS-PAGE. After the transfer of protein
onto Immobilon P membranes (Millipore Corporation) and blocking of the membrane
with 1% bovine serum albumin dissolved in TBST, primary antibodies were applied
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overnight. Secondary ImmunoPure antibody (α-mouse or α-rabbit), conjugated with
horseradish peroxidase (ThermoFisher), was applied onto the membrane for 1 h, and the
detection of signal was performed using the chemiluminescent SuperSignal West Dura or
Pico maximum-sensitivity substrate (ThermoFisher).

RNA Isolation, RT-PCR and qRT-PCR
Cells were plated in a 10 cm tissue culture plate and allowed to grow to semiconfluency. RNA was isolated using Tri Reagent according to the manufacturer’s
protocol (Sigma-Aldrich). cDNA was synthesized using ImPromII reverse transcriptase
(Promega) and an oligo(dT) primer. Primers for the 5’ and 3’ ends of the indicated genes
were used to amplify PCR products.
Quantitative qRT-PCR was conducted using the Absolute QPCR Sybr green kit
according to the manufacturer’s protocol (ABgene). The observed gene concentrations
were normalized using PGK1 expression levels.

Oxidative Stress and Antioxidant Defense PCR Array
The PCR Microarray was performed according to the manufacturer’s instructions
(SABiosciences, a QIAGEN company, Valencia CA). Gene expression was compared
according to the CT value. Normalization was performed for each cDNA sample using
the average of five housekeeping genes provided by manufacture.

Statistics
All assays were repeated at least three times, and the results reported as mean ±
standard deviation. Differences were analyzed by the Student’s t-test. P≤0.05 was
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regarded as significant.

Discussion
Oxidative stress has been found to be a contributing factor in cancer
tumorigenesis across a wide spectrum of cancers (Klaunig et al., 1995; Klaunig et al.,
1998; Toyokuni, 2008). Oxidative stress occurs when the balance between reactive
oxygen species (ROS) and cellular antioxidants is perturbed, a common occurrence in
cancer (Sies, 1997a). The free radicals thus generated are capable of activating
procarcinogens, altering the level of cellular antioxidant enzymes, and causing damage to
DNA and other biomolecules (Sun, 1990). ROS-induced DNA damage results in single
and double strand breaks, abasic sites, modified bases and DNA cross-linking (Demple &
Harrison, 1994; Marnett, 2000). This oxidative damage to DNA can then result in
chromosomal alterations that lead to cell transformation (Mani & Chinnaiyan, 2010). As
may be expected, the antioxidant enzyme system is found to be perturbed in cancer. For
example, the antioxidant enzyme, manganese superoxide dismutase (Mn-SOD), in
particular, is thought to function as a tumor suppressor (Bravard et al., 1992) as its
expression is found to be decreased in some transformed cell lines (Westman &
Marklund, 1981). Additionally, low activities of other cellular antioxidant enzymes such
as copper/zinc superoxide dismutase (CuZnSOD), catalase and glutathione peroxidase
1(Gpx1) are often observed in transformed cell lines (Li, Oberley, St Clair, Ridnour, &
Oberley, 1995). These findings correlate with the idea that oxidative stress functions as a
co-factor in carcinogenesis.
CaSki and SiHa cells are both HPV-16 transformed cervical cancer cell lines. In a
previous study, our laboratory demonstrated that the level of ROS as well as that of the
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antioxidant enzymes superoxide dismutase and glutathione peroxidase was significantly
different between these two cell lines (Williams et al., 2014). Specifically, CaSki cells
displayed higher levels of ROS and lower levels of antioxidant enzymes than did SiHa
cells. One consequence of the higher levels of ROS in CaSki cells was a higher level of
DNA damage. Further experiments employed NOK cells stably expressing only one of
the two isoforms (E6 or E6*) to investigate the effect of the HPV 16 E6 isoforms
individually. These experiments revealed that expression of E6*, but not E6, increased
the levels of ROS and oxidative DNA damage in these NOK cells. These findings are
consistent with those from the cancer cell lines, since CaSki cells had a higher E6*/E6
ratio, higher ROS levels, and more oxidative DNA damage than did the SiHa cells.
In the present study, we sought to identify those pathways and possibly individual
genes involved in ROS regulation in CaSki and SiHa cells that may be influenced by
HPV 16 E6. Because previous studies in our lab demonstrated that E6* is responsible for
the increasing ROS in cells, we postulated that the differences indentified in pathways
and gene expression between these cell lines may be due to the difference in E6*/E6
expression. The major source of ROS production in cells is the mitochondria, where
enzymes involved in the electron transport chain and the production of superoxide are
located (Balaban, Nemoto, & Finkel, 2005). ROS-producing enzymes identified in the
present study were expressed at higher levels in CaSki cells (Table 1), consistent with the
higher levels of ROS observed in these cells. On the other hand, the expression of
proteins with antioxidant functions was higher in SiHa than in CaSki cells. Examples of
such antioxidant enzymes include SOD1, SOD2, NQO1, PRDX and GPX (Figure 3 and
Table 1). Together, these differences in gene and protein expression may result in
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downstream changes in the level of cellular levels of ROS as measured by flow
cytometry (Figure 1B and 1C). Furthermore, these differences were also reflected in the
difference in levels of expression of proteins involved in DNA damage recognition and
response (Figure 3A), since these processes are activated during oxidative stress (Altieri,
Grillo, Maceroni, & Chichiarelli, 2008; Kryston, Georgiev, Pissis, & Georgakilas, 2011).
However, while these results provide a starting point for examining the influence of these
HPV 16 E6 isoforms on ROS, the fact that multiple copies of multiple viral genes, which
are also expressed at different levels, are present in these cells, combined with the lack of
matched controls, complicate the analysis of data from these cells and required the use of
another model system. Therefore, future studies will employ NOK cells that stably
express the different E6 isoforms separately to determine the individual effect of each
isoform on the pathways identified in CaSki and SiHa cervical cancer cells.
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CHAPTER FOUR
DISCUSSION

Summary of Findings
High Risk strains of Human Papillomavirus (HPV) are the causative agents of
most cases of cervical cancer as well as a significant proportion of oropharyngeal and
other anogenital cancers. The burden of cervical cancer has declined in recent decades
due to the efficiency of screening with the Pap smear, and is expected to decline even
further within the next few decades due to the influence of the HPV vaccines. However,
the incidence rate of other HPV-related cancers such as anal, oropharyngeal and vulvar
cancers has steadily increased within that same period. In addition, vaccine uptake rates
in the US remain at startling low levels (~33%) as compared to that seen in other first
world countries such as Canada, where vaccine uptake is as high as 75%in some regions
(Musto et al., 2013). This limits the expected influence of the vaccine on cervical cancer
incidence in upcoming decades. Treatment options for cervical cancer remain inadequate,
as one third of patients with invasive cervical cancer die from either recurrent or
metastatic disease (Tao, Hu, Ramirez, & Kavanagh, 2008). Each of these factors
underscores the need for ongoing research into the mechanisms behind HPV-related
carcinogenesis.
The experiments described in chapter two we present data demonstrating that the
E6* isoform of HPV 16 is able to increase ROS levels in cells, thereby causing increased
oxidative stress and DNA damage in these cells. In contrast, expression of the full-length
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isoform, E6L, displayed no significant effect on ROS. In this report, we also demonstrate
that changes in cellular ROS are associated with changes in the expression of antioxidant
enzymes such as SOD2 and Gpx (Figure 5). PARP, a cellular marker of DNA damage in
cells was also increased in CaSki cells as compared to SiHa cells, and in NOK E6*
compared to NOK pLNCX and NOK E6 cells. These findings are consistent with our
data showing that DNA damage is higher in E6*-expressing cell lines (Figure 6).
Superoxide dismutases are essential enzymes that eliminate superoxide radicals by
converting them to hydrogen peroxide (reviewed in (McCord & Edeas, 2005)).
Therefore, events that cause a decrease in SOD are predicted to result in an increase in
superoxide. Consistent with this prediction, we found that expressing E6* in NOK cells
resulted in both a decrease in SOD2 expression and an increase in ROS (Figures 5 and 4).
In addition, CaSki cells displayed lower levels of SOD2 than did SiHa cells, and these
lower levels of SOD2 were associated with higher levels of ROS (Figures 5 and 1). To
the best of our knowledge, this is the first study demonstrating a link between E6*
expression and oxidative stress in cells. These findings are significant, as they suggest
that HR HPV E6* may serve a significant role in generating oxidative DNA damage, and
that this increased oxidative stress may facilitate HPV-mediated carcinogenesis.
In chapter three, we observed differences in the ROS profiles of the cervical
cancer cell lines CaSki and SiHa. Therefore, in chapter three we asked which pathways
involved in ROS regulation might be influenced by the differential expression of the
HPV 16 E6 isoforms in these cells. Proteomic analysis enabled the identification of
several differentially-activated pathways that were involved not only in ROS regulation
but also in p53 activation and mitochondrial functioning. PCR analysis of an array of
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genes involved in ROS regulation then confirmed the differences in the expression levels
of several of the associated genes. We observed that in CaSki cells, as compared to SiHa
cells, several pro-oxidant genes such as AOX1 and OXR1 were up-regulated, while
antioxidant genes such as SOD1 and SOD2 were down-regulated. Further investigation
of these expression levels by immunoblotting and qRT-PCR validated our initial findings.
This data agrees with our earlier observation of increased ROS levels in CaSki versus
SiHa cells, since increased pro-oxidant and decreased antioxidants levels would lead to
the downstream observation of increased ROS levels.

Conclusions
Previous research has shown that expression of the high-risk HPV16 E6 oncogene
results in a greater frequency of foreign DNA integration into the host genome as
compared to expression of the low risk HPV E6 genes (Kessis, Connolly, Hedrick, &
Cho, 1996). As has been shown in studies of hepadnavirus, sites of DNA damage can
serve as sites for viral DNA integration, a critical step in carcinogenesis (S. Jeon & P.
Lambert, 1995; Petersen et al., 1997). Therefore, it is reasonable to expect that the
integration of HPV viral DNA into that of the host would also be enhanced by damage to
both the viral episome and the host DNA, as this would create a site for integration.
Studies such as those noted above and other similar findings led to our initial hypothesis
that expression of HPV 16 E6* may increase ROS levels in cells and lead to increased
levels of DNA damage in cells. Interestingly, only high-risk strains of HPV express the
E6* splice variant. With these facts in consideration, two questions were posed at the
beginning of these studies. 1) Does E6 isoform expression affect the level of cellular
oxidative stress in cells, and if so, what is/are the molecular mechanism(s)? This question
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was addressed in chapters 2 and 3. 2) Does expression of either of the E6 isoforms affect
the level of DNA damage in cells? This question was answered in chapter two.
In summary, the results from the experiments described in this dissertation show
for the first time that an HPV oncogene, E6*, can increase ROS levels in cells, decrease
expression of antioxidant enzymes and induce an increase in oxidative DNA damage.
They also show that in the CaSki and SiHa cervical cancer cell lines, difference in ROS
levels are reflected in differences observed in pathways connected to oxidative stress, as
identified at the protein level by proteomic analysis, IPA and immunoblotting, and at the
gene expression level by the Human Oxidative Stress and Antioxidant Defense PCR
Array and validated by RT PCR. Therefore, the overall findings of this study state that
HPV 16 E6* expression increases oxidative stress and DNA damage in cells though
pathways involved in ROS regulation.

Future Directions
In this thesis it was established that HPV16 E6* is capable of inducing oxidative
stress and DNA damage in both HPV+ and HPV- cells. One of the main molecular
implications of this finding is the putative functional role of HPV16 E6* in increasing the
frequency of HPV DNA integration. HPV DNA integration has been postulated as the
main molecular step in converting a benign HPV infection into a malignant disease
process such as cervical cancer. To date, few mechanisms for how HPV genome
integration occurs in HPV-induced carcinogenesis have been proposed. Studies in W12
cells demonstrated that increased DNA double-strand breaks are associated with HPV 16
integration in cervical keratinocytes (D. M. Winder et al., 2007). Cells with integrated
copies of HPV demonstrate increased proliferation and presumably form a pool of
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immortalized cells within which further mutations can occur, sometimes leading to full
transformation and cancer. Furthermore, the loss of E2 that occurs with integration allows
the increased expression of E6 and E7, which also promotes genetic instability and the
emergence of cancer.
Because HPV integration is frequently a pivotal step in the process of HPV
carcinogenesis, it is critical to determine the mechanisms by which HPV genes may
facilitate this event. Ongoing experiments in our lab are focused on developing
techniques that can be used to quantify HPV integration; these techniques will be used to
answer this question. To begin identifying the mechanisms involved in these E6*mediated changes in oxidative stress, we identified some of the pathways involved in
ROS regulation that may be influenced by HPV 16 E6 in CaSki and SiHa cells. However,
to determine the individual effect of each of these isoforms on the previously identified
pathways we plan to use the same NOK model system described in a chapter two, then
perform experiments similar to those outlined in chapter three. Through the use of this
model, we can then investigate the pathways involved in ROS metabolism that are
influenced separately by the HPV 16 E6 and E6* isoforms.
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